Canilang, Baby Boy .

HRN: 25-29-31  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/16/2024
AMPICILLIN 500MG (VIAL)
06/16/2024
06/22/2024
IV
145mg
Q12h
Potentially Septic Newborn
Waiting Final Action 
06/16/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
06/16/2024
06/22/2024
IV
14.5mg
OD
Potentially Septic Newborn
Waiting Final Action 
06/17/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/17/2024
06/24/2024
IVT
44mg LD Then 22mg
Q8
GI Obstruction
Waiting Final Action 
06/17/2024
AMPICILLIN 500MG (VIAL)
06/17/2024
06/24/2024
IVT
290mg
Q12
GI Obstruction
Waiting Final Action 
06/20/2024
MUPIROCIN 2%, 15G (TUBE)
06/20/2024
06/26/2024
TOPICAL
1
BID
Bacterial Skin Infection
Waiting Final Action 
06/23/2024
CEFOTAXIME 500MG (VIAL)
06/23/2024
06/30/2024
IV
125 Mg
Q 12
T/C Neonatal Sepsis
Waiting Final Action 
06/23/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/23/2024
06/30/2024
IV
38mg
Q 24
T/C Neonatal Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: